Vol. 19/No. 3

A factor contributing to better outcomes is better collaboration between physicians and their patients throughout the entire care process.

Hope S. Rugo, MD, discusses the importance of individualizing doses of nab-paclitaxel in triple-negative breast cancer.

ALK inhibitors have followed a rapid trajectory from bench to bedside, taking over from chemotherapy as standard frontline treatment for patients with advanced non– small-cell lung cancer with ALK gene rearrangements.

A recent study of oncologists’ use of next-generation sequencing to test for actionable genetic mutations reveals a stark gap between the appropriateness and the actual utilization of these tests.

The pan-TRK inhibitor entrectinib (RXDX101) is being tested simultaneously in multiple locally advanced or metastatic solid tumor types as a treatment for patients harboring fusions involving the NTRK1/2/3, ROS1, or ALK genes.

Novel systemic therapies in the neoadjuvant and adjuvant settings have shown promising outcomes for locally advanced melanoma and may reduce the proportion of patients who need complete lymphadenectomy.

Despite positive clinical trial results, the role of immunotherapy in renal cell carcinoma remains unclear.

The gene-editing tool known as CRISPR may eventually enable oncology investigators to create methods for killing tumors directly, but thus far, the focus is on enhancing forms of immunotherapy already in clinical practice.

Emerging data have confirmed that ovarian cancer is a much more heterogeneous disease than previously recognized.

The FDA’s recent approvals of novel anti-PARP agents as maintenance therapy for patients with previously treated advanced ovarian cancer highlight an issue that has received inadequate attention in the peer-reviewed oncology literature.